Your browser is no longer supported. Please, upgrade your browser.
Settings
AIM [AMEX]
AIM ImmunoTech Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.60% Shs Outstand40.89M Perf Week-6.67%
Market Cap100.90M Forward P/E- EPS next Y-0.37 Insider Trans14.38% Shs Float40.09M Perf Month-12.86%
Income-14.40M PEG- EPS next Q-0.09 Inst Own6.50% Short Float3.92% Perf Quarter3.96%
Sales0.20M P/S504.52 EPS this Y82.50% Inst Trans13.52% Short Ratio0.54 Perf Half Y-14.29%
Book/sh1.48 P/B1.42 EPS next Y-5.70% ROA-26.00% Target Price- Perf Year-14.98%
Cash/sh0.81 P/C2.59 EPS next 5Y25.00% ROE-28.60% 52W Range1.60 - 4.30 Perf YTD17.32%
Dividend- P/FCF- EPS past 5Y57.90% ROI-23.90% 52W High-51.16% Beta-0.81
Dividend %- Quick Ratio36.60 Sales past 5Y4.20% Gross Margin- 52W Low31.25% ATR0.11
Employees21 Current Ratio36.60 Sales Q/Q-16.00% Oper. Margin- RSI (14)40.02 Volatility3.60% 5.13%
OptionableNo Debt/Eq0.03 EPS Q/Q19.20% Profit Margin- Rel Volume0.18 Prev Close2.11
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume2.92M Price2.10
Recom2.00 SMA20-7.73% SMA50-10.50% SMA200-6.89% Volume522,174 Change-0.47%
Apr-07-21 09:15AM  
Mar-31-21 09:15AM  
Mar-22-21 08:45AM  
Mar-11-21 07:00AM  
Mar-10-21 06:55AM  
Mar-08-21 09:15AM  
Mar-04-21 06:50AM  
Feb-24-21 09:15AM  
Feb-16-21 09:15AM  
Feb-10-21 09:15AM  
Feb-05-21 06:50AM  
Jan-29-21 06:55AM  
Jan-15-21 06:45AM  
Jan-11-21 06:45AM  
Jan-06-21 06:45AM  
Dec-24-20 09:05AM  
07:52AM  
Dec-21-20 09:40AM  
06:45AM  
Nov-25-20 06:45AM  
Nov-15-20 07:01AM  
07:00AM  
Nov-13-20 07:30AM  
Nov-02-20 09:00AM  
Oct-30-20 10:00AM  
Oct-22-20 07:30AM  
Oct-06-20 09:00AM  
Sep-22-20 06:50AM  
Sep-16-20 06:50AM  
Sep-10-20 06:50AM  
Sep-08-20 06:50AM  
Aug-31-20 05:00PM  
Aug-27-20 09:15AM  
Aug-25-20 06:55AM  
Aug-21-20 11:18AM  
Aug-17-20 09:18AM  
06:55AM  
Aug-05-20 09:00AM  
Aug-03-20 08:00AM  
Jul-27-20 06:55AM  
Jul-09-20 06:30AM  
Jul-06-20 09:00AM  
Jun-29-20 06:55AM  
Jun-15-20 08:00AM  
Jun-11-20 09:05AM  
May-14-20 06:50AM  
Apr-29-20 06:30AM  
Apr-20-20 06:30AM  
Apr-06-20 06:30PM  
01:00PM  
06:30AM  
Mar-31-20 06:45AM  
Mar-26-20 08:00AM  
Mar-09-20 06:30AM  
Mar-08-20 11:34AM  
Feb-27-20 06:30AM  
Feb-18-20 06:30AM  
Feb-12-20 06:30AM  
Feb-11-20 06:30AM  
06:30AM  
Feb-05-20 06:30AM  
Jan-16-20 05:27AM  
Dec-11-19 12:20PM  
06:30AM  
Dec-04-19 06:30AM  
Nov-15-19 10:25AM  
06:30AM  
Oct-23-19 06:30AM  
Oct-07-19 06:30AM  
Sep-25-19 09:50AM  
Sep-24-19 06:30AM  
06:00AM  
Sep-19-19 08:43AM  
06:50AM  
Sep-16-19 06:50AM  
Sep-13-19 06:50AM  
Sep-10-19 07:30AM  
Sep-09-19 07:45AM  
Sep-06-19 06:30AM  
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
APPELROUTH STEWARTDirectorFeb 25Buy2.3510,63824,99992,538Feb 25 03:07 PM
EQUELS THOMAS K.CEO & PresidentFeb 24Buy2.2611,06225,000209,630Feb 24 12:03 PM
EQUELS THOMAS K.CEODec 17Buy1.7214,53525,000198,568Dec 17 12:22 PM
EQUELS THOMAS K.CEO & PresidentSep 03Buy2.0312,31625,001184,033Sep 03 10:53 AM
EQUELS THOMAS K.CEOAug 21Buy2.3310,73025,001171,717Aug 21 08:08 AM